Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGLBiotechnology
-$1.33 today
- Market cap
- $9.25B
- Beta
- -1.06
- P/E (TTM)
- -46.9
- EPS (TTM)
- -$10.66
Volume 0.64M
Average 0.31M
MDGL Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL
Gross Margin · Q2 FY2026 · quarter ended Jun 2026
Gross margin narrows to 89.0%
Gross margin was 89.0% in Q2 FY2026, down 6.7 pp from a year earlier. On a trailing-twelve-month basis it was 91.5%, down 4.8 pp year over year.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 94.1%
- Year-over-year change
- -2.4pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 94.1% | -2.4pp |
| FY2024 | 2024-12-31 | 96.5% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Gross Margin vs competitors
How MDGL compares with its peers on the latest reported figures
- MDGL's LTM Jun 2026 gross margin of 91.5% is the 3rd highest of the 5 companies compared; the peer median is 62.9%.
- Its year-over-year change of -4.8 pp is the highest of 5, against a peer median of -37.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 92.1% | -7.9 pp | -0.3 pp | |
| LTM Mar 2026 | 92.0% | -8.0 pp | — | |
| LTM Jun 2026 | 91.5% | -4.8 pp | — | |
| FY2025 | 33.7% | -66.3 pp | -106.4 pp | |
| LTM Mar 2026 | -41519.4% | -41619.4 pp | +0.0 pp | |
| FY2025 | — | — | — | |
SGMTSagimet Biosciences Inc. | FY2025 | — | — | — |
| Peer median (excluding MDGL) | 62.9% | -37.1 pp | -0.3 pp | |
Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 180.13M | 958.4M |
| Cost of Revenue | 0 | 0 | 0 | 6.23M | 56.15M |
| Gross Profit | 0 | 0 | 0 | 173.9M | 902.26M |
| Gross Margin | — | — | — | 96.5% | 94.1% |
| Research & Development | 205.16M | 245.44M | 272.35M | 236.72M | 388.53M |
| Selling, General & Admin | 37.32M | 48.13M | 108.15M | 435.06M | 813.83M |
| Operating Expenses | 242.48M | 293.57M | 380.5M | 671.78M | 1.2B |
| Depreciation & Amortization | 405K | 467K | 527K | 1.1M | 1.51M |
| EBITDA | (241.44M) | (290.92M) | (360.39M) | (450.13M) | (264.47M) |
| EBITDA Margin | — | — | — | -249.9% | -27.6% |
| Operating Income | (242.48M) | (293.57M) | (380.5M) | (497.88M) | (300.1M) |
| Operating Margin | — | — | — | -276.4% | -31.3% |
| Interest Income | 363K | 2.19M | 19.58M | 46.65M | 37.36M |
| Interest Expense | 0 | 3.96M | 12.71M | 14.67M | 22.31M |
| Other Income / Expenses | 636K | (1.78M) | 6.87M | 31.98M | 11.81M |
| Income Before Tax | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Pre-Tax Margin | — | — | — | -258.6% | -30.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Net Margin | — | — | — | -258.6% | -30.1% |
| EPS (Basic) | (14.63) | (17.23) | (19.99) | (21.90) | (12.85) |
| EPS (Diluted) | (14.63) | (17.23) | (19.99) | (21.90) | (12.85) |
| Weighted Avg Shares | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M |
| Weighted Avg Shares (Diluted) | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M |
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
Intrinsic Alpha fair value
Locked
Current Price
$398.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.